Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Durvalumab + Pemetrexed Disodium |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA-approved for use in patients with urothelial carcinoma, unresectable, stage III non-small cell lung cancer, and limited-stage small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with platinum-based chemotherapy as neoadjuvant therapy followed by surgery and adjuvant Imfinzi (durvalumab) in patients with resectable non-small cell lung cancer, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with carboplatin plus paclitaxel followed by single-agent Imfinzi (durvalumab) in adult patients with mismatch repair deficient endometrial cancer (FDA.gov). |
Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05624996 | Phase III | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04585490 | Phase III | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Paclitaxel | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | Recruiting | USA | 0 |
NCT04105270 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial | Recruiting | USA | 0 |
NCT03800134 | Phase III | Cisplatin + Durvalumab + Gemcitabine Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Gemcitabine | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer | Active, not recruiting | USA | ROU | POL | NLD | ITA | HUN | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | ARG | 13 |
NCT04262869 | Phase II | Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Durvalumab | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | Withdrawn | 0 | |
NCT03944772 | Phase II | Necitumumab + Osimertinib Osimertinib + Selpercatinib Alectinib + Osimertinib Carboplatin + Durvalumab + Pemetrexed Disodium Osimertinib + Savolitinib Gefitinib + Osimertinib | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD) | Active, not recruiting | USA | SWE | NOR | NLD | ITA | ESP | DNK | 2 |
NCT04163432 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium | Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC (STAGGER) | Recruiting | USA | 0 |
NCT04470674 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients | Withdrawn | USA | 0 |
NCT03775486 | Phase II | Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) | Active, not recruiting | USA | POL | NLD | HUN | GBR | BEL | 6 |
NCT04765709 | Phase II | Cisplatin + Dulanermin + Vinorelbine Carboplatin + Durvalumab + Vinorelbine Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (BRIDGE) | Active, not recruiting | ITA | FRA | ESP | 0 |